On A Tumor’s Turf

On A Tumor’s Turf

TACKLING THE SPACE AROUND SOLID TUMORS Covering the science behind T-cell-based immunotherapies has been the name of the game for our past couple of issues. CAR-T and TCR therapies show significant promise in early phase blood cancer clinical trials, but what about...
Battling CLL: Venclexta

Battling CLL: Venclexta

 Pushing the Self-Destruct Button Breakthrough drug Venclexta charged onto the marketplace three months early to battle chronic lymphocytic leukemia. AbbVie’s (North Chicago, IL) and Roche’s (Basel, Switzerland) new therapy gained a quick approval after 80% of...
Feeding Cancer

Feeding Cancer

The Metabolics Of Cancer Tackling cancer requires a multi-pronged strategy. Currently, many of the cancer drugs on the market work by inhibiting the signaling pathways that activate cell division. These pathways are often the root cause of cancer—a mutated gene leads...
New Hope For Basal Cell Carcinoma

New Hope For Basal Cell Carcinoma

The Science Behind The Latest FDA Approval Strong Phase II data launched Novartis’ (Basel, Switzerland) Odomzo to an accelerated FDA approval for basal cell carcinoma last week. The company skipped Phase III testing for the skin cancer drug because 58% of...

Can Cell Death Keep Cancer Patients Alive?

Programmed cell death is making a name for itself as a pathway in cancer drug development. We asked ourselves: what is this process known as apoptosis and why is it a sought after drug target? Apoptosis is a system that evolved in cells for detecting damage to DNA and...